Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Up 87.3% in January

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) was the target of a significant growth in short interest in January. As of January 30th, there was short interest totaling 12,685,342 shares, a growth of 87.3% from the January 15th total of 6,772,644 shares. Currently, 4.9% of the shares of the stock are short sold. Based on an average daily volume of 5,603,339 shares, the short-interest ratio is presently 2.3 days. Based on an average daily volume of 5,603,339 shares, the short-interest ratio is presently 2.3 days. Currently, 4.9% of the shares of the stock are short sold.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX opened at $14.63 on Friday. The company has a market cap of $4.60 billion, a P/E ratio of 731.87 and a beta of 1.36. The stock has a 50-day moving average of $13.23 and a two-hundred day moving average of $11.23. Amneal Pharmaceuticals has a 1-year low of $6.68 and a 1-year high of $15.00.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Ted C. Nark sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $11.72, for a total transaction of $586,000.00. Following the transaction, the director owned 291,029 shares in the company, valued at approximately $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 26.56% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Spire Wealth Management raised its stake in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after buying an additional 1,023 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Amneal Pharmaceuticals by 1.2% in the 4th quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after acquiring an additional 1,159 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Amneal Pharmaceuticals by 2.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after acquiring an additional 1,582 shares in the last quarter. Comerica Bank lifted its stake in Amneal Pharmaceuticals by 56.1% during the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after purchasing an additional 1,685 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Piper Sandler reiterated an “overweight” rating and set a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Truist Financial set a $15.00 target price on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Barclays initiated coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $15.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $13.80.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.